A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.

Trial Profile

A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Icotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Zhejiang Beta Pharma
  • Most Recent Events

    • 13 Feb 2014 As per the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 27 Dec 2013 Planned End Date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 05 Jun 2013 Planned End Date changed from 1 Aug 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top